Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIP versus placebo in pulmonary arterial hypertension
2021-001528-16Phase 2Active
- Sponsor
- Insmed Incorporated
- Start
- Mar 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing TPIP with Placebo (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance. Started Mar 2022; status: active.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-001528-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001528-16.